AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
YM Loo, PM McTamney, RH Arends, RA Gasser Jr… - Medrxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies …
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
[HTML][HTML] Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Y Ji, Q Zhang, L Cheng, J Ge, R Wang, M Fang… - Frontiers in …, 2022 - frontiersin.org
Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating …
2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating …
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
BE Jones, PL Brown-Augsburger, KS Corbett… - Science translational …, 2021 - science.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …
[HTML][HTML] Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - nature.com
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
[HTML][HTML] A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
Y Guo, L Huang, G Zhang, Y Yao, H Zhou… - Nature …, 2021 - nature.com
COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …
[HTML][HTML] Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
X Chi, X Liu, C Wang, X Zhang, X Li, J Hou… - Nature …, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
[HTML][HTML] A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
X Chi, R Yan, J Zhang, G Zhang, Y Zhang, M Hao… - BioRxiv, 2020 - biorxiv.org
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) presents a global public health threat. Most …
syndrome coronavirus 2 (SARS-CoV-2) presents a global public health threat. Most …